Cincinnati-based Medpace, a privately held CRO, has acquired MediTech Strategic Consultants, a European CRO dedicated to medical device clinical trials and services related to development and commercialization of medical devices.

MediTech expands Medpace's European device capabilities both in the development of trial designs and regulatory strategies toward CE Mark, in addition to the conduct of clinical trials and authorized representative and quality system support toward ISO 13485. The acquisition, combined with Medpace's existing medical device division, provides a global solution for medical device development.

MediTech was founded in 2000 by Carla Kikken-Jussen, president and CEO. MediTech has supported clinical trials of medical devices in therapeutic areas including ophthalmology, cardiovascular, gastroenterology, orthopedics and pulmonology. Kikken-Jussen will continue to lead MediTech.

“MediTech's expertise complements and broadens our global medical device service offering,” said Dr. August Troendle, president and CEO of Medpace. “MediTech is well respected in both Europe and the U.S., and this strategic acquisition fully supports Medpace's growth and provides our sponsors a wide range of regulatory and clinical expertise across North America and Europe, along with expanded operational capacity."

Medpace provides phase I-IV core development services for drug, biologic, and device programs. It has more than 1,200 employees and clinical trial experience in over 40 countries. Medpace also provides phase I/IIa clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from Imagepace and medical device development from Medpace Medical Device.

MediTech Strategic Consultants employs more than 40 multinational staff based in the Netherlands, the Czech Republic, Israel and Poland, providing support for trials conducted throughout the European Union and Israel, Norway, Switzerland and Turkey.